Subscribe to Journal
Get full journal access for 1 year
only $102.00 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Tricot G, Vesole DH, Jagannath S, Hilton J, Munshi N, Barlogie B . Graft-versus-myeloma effect: proof of principle. Blood 1996; 87: 1196–1198.
Bjorkstrand B, Iacobelli S, Hegenbart U, Gruber A, Greinix H, Volin L et al. Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up. J Clin Oncol 2011; 29: 3016–3022.
Gahrton G, Iacobelli S, Bjorkstrand B, Hegenbart U, Gruber A, Greinix H et al. Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study. Blood 2013; 121: 5055–5063.
Bruno B, Rotta M, Patriarca F, Mordini N, Allione B, Carnevale-Schianca F et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med 2007; 356: 1110–1120.
Krishnan A, Pasquini MC, Logan B, Stadtmauer EA, Vesole DH, Alyea E 3rd et al. Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. Lancet Oncol 2011; 12: 1195–1203.
Garban F, Attal M, Michallet M, Hulin C, Bourhis JH, Yakoub-Agha I et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood 2006; 107: 3474–3480.
Rosinol L, Perez-Simon JA, Sureda A, de la Rubia J, de Arriba F, Lahuerta JJ et al. A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. Blood 2008; 112: 3591–3593.
Armeson KE, Hill EG, Costa LJ . Tandem autologous vs autologous plus reduced intensity allogeneic transplantation in the upfront management of multiple myeloma: meta-analysis of trials with biological assignment. Bone Marrow Transplant 2013; 48: 562–567.
Network NCC. NCCN clinical practice guidelines in oncology (NCCN Guidelines). Multiple myeloma. Version 3. 2016. Available at: http://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf (accessed 24 May 2016).
Kronke J, Udeshi ND, Narla A, Grauman P, Hurst SN, McConkey M et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science 2014; 343: 301–305.
Lu G, Middleton RE, Sun H, Naniong M, Ott CJ, Mitsiades CS et al. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science 2014; 343: 305–309.
Eichner R, Heider M, Fernandez-Saiz V, van Bebber F, Garz AK, Lemeer S et al. Immunomodulatory drugs disrupt the cereblon-CD147-MCT1 axis to exert antitumor activity and teratogenicity. Nat Med 2016; 22: 735–743.
Krönke J, Kuchenbauer F, Kull M, Teleanu V, Bullinger L, Bunjes D et al. IKZF1 expression is a prognostic marker in newly diagnosed standard-risk multiple myeloma treated with lenalidomide and intensive chemotherapy: a study of the German Myeloma Study Group (DSMM). Leukemia 2017; 31:1363–1367.
Cavo M, Tosi P, Zamagni E, Cellini C, Tacchetti P, Patriarca F et al. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol 2007; 25: 2434–2441.
Knop S, Gerecke C, Liebisch P, Topp MS, Platzbecker U, Sezer O et al. Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom). Blood 2009; 113: 4137–4143.
We thank all patients and families involved in the trial reported. Financial support for the trial was provided by Wilhelm Sander-Stiftung; grant number 2013.900.1. Medical writing support was provided by Sandralee Lewis, PhD, of the Investigator Initiated Research Writing Group (an initiative from Ashfield Healthcare Communications, part of UDG Healthcare plc) and was funded by Celgene Corporation. The trial was supported by financial grants from Celgene Germany GmbH, Amgen Germany GmbH and medac GmbH.
SK, HE and RCB were responsible for the conception and design of the study. ME, CL, AR, WR, BH, AK, CR and HB provided study materials or patients. SK, CL, L-OM, WR, FB, BH, AK, CR, HO, KS-E, MR, AG, CJ, HB, MS and AL collected and assembled the data. SK, CL, ME, BH, CR, SH, HE and RCB analyzed and interpreted the data. SK wrote the first draft of the manuscript. All the authors critically reviewed the manuscript and approved the final draft.
The authors were fully responsible for all content and editorial decisions during the development of this manuscript, and approved the final version.
Stock ownership: WR, Amgen, Immunomedics. Honoraria: SK, Celgene Germany, Amgen Germany, BMS Germany, ONYX Inc., Janssen Germany; ME, Celgene, Janssen, MSD, Amgen; L-OM, Celgene, Janssen-Cilag, Novartis; FB, Celgene; MR, Celgene; AG, Novartis, Celgene, Janssen; MS, Novartis; HE, Janssen, Amgen, Novartis, Celgene; RCB, Amgen, Novartis, GeoMab. Consultant or advisory role: SK, Celgene Germany, Amgen Germany, Celgene Inc.; CL, Celgene, Janssen, Amgen, Novartis, Takeda, BMS; ME, Celgene, Janssen, MSD, Amgen; WR, Janssen, MSD; FB, Celgene; BH, Amgen; CR, Amgen, BMS, Celgene, Janssen, Roche, Takeda; HO, MSD, Gilead, AstraZeneca, Teva; AG, Novartis, Takeda; HB, BMS, Roche, Pfizer, MSD, Sanofi; HE, Janssen, Celgene, Amgen; RCB, Amgen, Novartis, GeoMab. Speakers’ bureau: CR, Amgen, BMS, Celgene, Janssen, Roche, Takeda; HO, MSD, AstraZeneca, Novartis, Teva; HE, Janssen, Celgene, Novartis. Research funding: L-OM, Celgene; FB, Celgene; CR, Bayer; HO, MSD, Genzyme, Cereus; HE, Amgen, Celgene, Janssen. Patents, royalties, other intellectual property: RCB, Amgen. Travel, accommodation, expenses: CL, Celgene, Takeda, BMS; ME, Celgene, Janssen, MSD, Amgen; L-OM, Novartis, Celgene; WR, medac, Janssen, MSD; FB, Celgene, BMS; BH, Teva, Amgen, Novartis, Neovi; CR, Amgen, Celgene, Janssen, Gilead; HO, MSD, Gilead, AstraZeneca; MR, medac; HB, Jazz, Eusapharma, Sanofi, Amgen; MS, Celgene; RCB, Amgen, Novartis, GeoMab. The remaining authors declare no conflict of interest.
Supplementary Information accompanies this paper on the Leukemia website
About this article
Cite this article
Knop, S., Langer, C., Engelhardt, M. et al. Lenalidomide, adriamycin, dexamethasone for induction followed by stem-cell transplant in newly diagnosed myeloma. Leukemia 31, 1816–1819 (2017). https://doi.org/10.1038/leu.2017.124
Venous thromboembolism risk with contemporary lenalidomide-based regimens despite thromboprophylaxis in multiple myeloma: A systematic review and meta-analysis
Usnea Acid as Multidrug Resistance (MDR) Reversing Agent against Human Chronic Myelogenous Leukemia K562/ADR Cells via an ROS Dependent Apoptosis
BioMed Research International (2019)
Effect of induction therapy with lenalidomide, doxorubicin and dexamethasone on bone remodeling and angiogenesis in newly diagnosed multiple myeloma
International Journal of Cancer (2019)
Der Onkologe (2018)
Maintaining therapeutic progress in multiple myeloma by integrating genetic and biological advances into the clinic
Expert Review of Hematology (2018)